---
title: "Dizal Pharmaceutical (688192.SH) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688192.SH/norm.md"
symbol: "688192.SH"
name: "Dizal Pharmaceutical"
parent: "https://longbridge.com/en/quote/688192.SH.md"
datetime: "2026-03-10T04:31:17.926Z"
locales:
  - [en](https://longbridge.com/en/quote/688192.SH/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688192.SH/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688192.SH/norm.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688192.SH/norm.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688192.SH/norm.md)


# Dizal Pharmaceutical (688192.SH) — Financial Reports

## Income Statement (CNY)

| Indicator | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.3923 | -0.4496 | -0.4117 | -0.4600 | -0.6883 |
| ROE | -50.92% | -52.88% | -90.03% | -725.73% | -369.66% |
| Revenue | 214.83M | 231.30M | 195.36M | 159.64M | 21.45M |
| Net income | -183.36M | -202.59M | -184.85M | -192.51M | -287.50M |
| Operating income | -187.61M | -174.24M | -215.35M | -189.17M | -323.55M |
| Gross margin | 111.79% | 95.81% | 95.62% | 95.57% | 80.67% |
| Net margin | -85.35% | -87.59% | -94.62% | -120.59% | -1340.33% |
| Profit quality | - | - | - | - | - |

## Balance Sheet (CNY)

| Indicator | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
| --- | --- | --- | --- | --- | --- |
| A&L | - | 2.96B | 3.22B | 1.80B | 1.72B |
| Leverage | - | 2.05 | 1.98 | 76.69 | 8.59 |
| BVPS | - | 3.14 | 3.54 | 0.0442 | 0.4639 |
| Turnover | - | 0.2644 | 0.2103 | 0.2611 | 0.2239 |
| Cash & STI | - | 1.93B | 2.25B | 898.76M | 839.99M |
| Inv & Rec | - | 38.54M | 40.55M | 37.54M | 44.11M |
| LT assets | - | 375.27M | 342.81M | 280.29M | 243.91M |
| Net debt | - | -864.17M | -1.07B | 531.38M | 317.39M |

## Cash Flow Statement (CNY)

| Indicator | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | - | -159.39M | -133.00M | -131.67M | -187.22M |
| Investing CF | - | 65.19M | -388.58M | -128.65M | 48.54M |
| Financing CF | - | -135.47M | 1.51B | 262.62M | 260.21M |
| Free CF | - | -225.70M | -71.43M | -166.80M | 33.10M |
| OCF coverage | - | -109.08% | -28.18% | -66.65% | -225.08% |
| Repaid & issued | - | 0.0000 | 165.87M | 391.34M | 259.88M |
| CapEx | - | -37.11M | -37.00M | -75.83M | -43.50M |